Literature DB >> 9554071

Innate and cell-mediated immune responses to Cryptosporidium parvum.

C M Theodos1.   

Abstract

Cryptosporidium parvum has gained much attention as a major cause of diarrhea in the world. Knowledge of the host immune mechanisms responsible for the clearance of this parasite from the gastrointestinal tract may prove to be vital for successful therapeutic treatment of cryptosporidiosis, particularly in the immunodeficient host. This chapter focuses on the innate and cell-mediated immune mechanisms associated with resistance to and resolution of a C. parvum infection. Much of the work in these areas is still in its infancy. Despite this, general consensus supports a role for interferon-gamma (IFN gamma) in mediating the initial resistance to C. parvum, although the mechanism by which this cytokine imparts resistance is unclear. It is also generally agreed that CD4+ T lymphocytes are required for the resolution of both acute and chronic cryptosporidiosis. However, the effector mechanism is again unclear. Several studies suggest that IFN gamma may also be involved in the resolution of cryptosporidiosis. However, the extent to which this cytokine is involved in the actual resolution of infection has been debated. Less extensive studies investigating the participation of other cells and cytokines in the innate and cell-mediated immune responses to C. parvum are also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554071     DOI: 10.1016/s0065-308x(08)60118-9

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  19 in total

1.  Human intestinal and biliary cryptosporidiosis.

Authors:  Xian-Ming Chen; Nicholas F LaRusso
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  Cryptosporidiosis: environmental, therapeutic, and preventive challenges.

Authors:  S Collinet-Adler; H D Ward
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

4.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

5.  Role of tumor necrosis factor alpha in development of immunity against Cryptosporidium parvum infection.

Authors:  I-Sarah Lean; Sonia Lacroix-Lamandé; Fabrice Laurent; Vincent McDonald
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice.

Authors:  K A Rogers; A B Rogers; B A Leav; A Sanchez; E Vannier; S Uematsu; S Akira; D Golenbock; H D Ward
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  An early intestinal mucosal source of gamma interferon is associated with resistance to and control of Cryptosporidium parvum infection in mice.

Authors:  Brett A Leav; Masaru Yoshida; Kathleen Rogers; Seth Cohen; Nihal Godiwala; Richard S Blumberg; Honorine Ward
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Recombinant proteins of Cryptosporidium parvum induce proliferation of mesenteric lymph node cells in infected mice.

Authors:  Inderpal Singh; Cynthia Theodos; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

9.  Role of murine Peyer's patch lymphocytes against primary and challenge infections with Cryptosporidium parvum.

Authors:  Sang-Mee Guk; Jong-Yil Chai
Journal:  Korean J Parasitol       Date:  2007-09       Impact factor: 1.341

10.  Cryptosporidiosis in paediatric renal transplantation.

Authors:  Flavio Bandin; Theresa Kwon; Marie-Denise Linas; Vincent Guigonis; Alexis Valentin; Sophie Cassaing; Agnes Carol; Arnaud Garnier; Veronique Baudouin; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2009-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.